overview for cure of aids, cancer and opiate addiction
TRANSCRIPT
8/7/2019 Overview for Cure of AIDS, cancer and Opiate Addiction
http://slidepdf.com/reader/full/overview-for-cure-of-aids-cancer-and-opiate-addiction 1/1
One Page Overview
MISSION: To cure cancer, AIDS, opiate addictions, and to preventpandemics, infections, and to protect and preserve human brains,while becoming industry leader in medical technology and in profit.PRODUCTS: (1) Treating cancers & AIDS with whole-body profoundhyperthermia system, (2) Prevent Brain and Spinal Cord damage withhypothermia system, (3) Reduce hospital-acquired infections andpublic space pandemics with UV System (4) Stop opiate addictionwithout withdrawal in 8 hours & no relapse with Advanced Rapid Detoxsystem
TECHNOLOGY : US PATENT NUMBER 6669661 AND RELATED KEY TECHNOLOGIES
Please see our websites: www.hypermed.us and www.rapiddetoxlasvegas.com
MARKET: (1) THERE ARE APPROXIMATELY 500,000 CANCER PATIENTS AND AIDS PATIENTS WORLD WIDE WHO CAN AFFORD $30,000 TREATMENT TO CURE CANCER AND AIDS. (2)100,000 PATIENTS IN THE US WHO SUFFER BRAIN DAMAGE DUE TO CARDIAC ARREST, STROKE,OR TRAUMA, (3) 5,000 HOSPITALS AND 20,000 NURSING HOMES AND NUMEROUS SCHOOLS AND PULBIC SPACES THAT WISH TO PREVENT INFECTION AND PANDEMICS (4) 40,000 AMERICANS WHO DIE ANNUALLY FROM OPIATE OVERDOSE, ASSUMING 4000 SUCH PATIENTS CAN AFFORD TO PAY $15,000 FOR RAPID DETOX PROCEDURE TO STOP ADDICTION.
BUSINESS MODEL: SELL DEVICES, TECHNOLOGY, TRAINING AND FRANCHISE
INTELLECTUAL PROPERTY : HYPERMED, INC. OWNS UNITED STATES PATNET 6669661WHICH INCLUDES THE KEY TECHNOLOGY.
COMPETITION: THERE IS NO OTHER CURE FOR CANCER, FOR AIDS, FOR OPIATE ADDICTION
MILESTONES : HYPERMED IS GENERATING REVENUE CURRENTLY AT 1 MILLION USD PER YEAR,MAINLY FROM RAPID DETOX WHICH STOPS OPIATE ADDICTION IN 8 HOURS WITHOUT WITHDRAWAL OR
RELAPSE. NEXT MILESTONE WOULD BE FIELD TESTING OF PORTABLE HIGH-OUTPUT ULTRA VIOLET DEVICE TO RAPIDLY SANITIZING LARGE AREAS IN HOSPITALS AND PUBLC SPACES. NEXT MILESTONE ISSUCCESSFUL COMPLETION OF ANIMAL TESTING OF HYPERTHERMIA AND HYPOTHERMIA SYSTEMS AT
UTAH ARTIFICIAL HEART CENTER
MANAGEMENT: THOMAS C. YEE, MD MBA, CEOMATTHEW COOPER, MD, DIRECTOR
K EVIN MURRAY, MD, DIIRECTOR
Hypermed, Inc.www.hyperme.us
www.rapiddetoxlasvegas.omww
Contact:Hypermed, Inc.Dr. Thomas Yee, MD MBA
Industry:Medical technology
Company LaunchDate:8/8/2003
Number of Employees:5
Strategic
Partnerships:
Current Users &Customers:330 satisfied patients
Do you have aDemo orPrototype?Yes
Current Investors:Primary Care, Inc.
Amount Sought forWhich Round:10 to 20 million USDfirst round
MinimumInvestment perInvestor:$200,000
Valuation:$20,000,000
Use of Funds:Expansion of operations
Burn Rate(current):$50,000 per month
Current Revenue:
1 million USD peryear